Key Takeaways
- A biomarker report is not a treatment prescription. Confirm the specimen, assay, exact alteration, evidence level and disease context before searching trials.
- “Pathogenic,” “actionable,” “drug approved” and “trial eligible” are different conclusions.
- Tissue and plasma tests answer overlapping but not identical questions; a negative liquid biopsy may be uninformative when little tumour DNA is shed.
- A biomarker match still has to satisfy tumour type, stage, prior-treatment, measurable-disease, organ-function, washout and site-specific cohort criteria.
- Basket, umbrella and platform trials organise matching differently. Verify the exact arm and recruitment status at the Chinese site, not just the master protocol.
Content
Precision oncology is not the act of uploading a sequencing report and receiving the name of a drug. It is a chain of clinical and laboratory judgments. A break at any link—wrong specimen, an assay that cannot detect the required alteration, a variant of uncertain significance, evidence from another cancer, or a closed cohort—can turn an apparently perfect match into no match at all.
NCI describes biomarker testing as analysis of genes, proteins or other features that may help select cancer treatment, while stressing that testing does not help every patient and that even a matching therapy may not work [1]. The sensible output of matching is therefore a ranked set of options and uncertainties, not a promise.
Start with the clinical question
Before ordering another panel, define what decision the result could change:
- Is there a standard biomarker required for an approved treatment in this tumour type?
- Is the goal to find a trial after standard options, explain resistance, or identify an inherited-risk clue?
- Does the proposed trial require a particular alteration, assay, sample type or central laboratory?
- Is new tissue medically safe and likely to produce enough viable tumour?
Testing without a decision point can produce a long report and no usable action. Conversely, a narrow single-gene test may be enough when the protocol asks one specific question.
Build the “biomarker identity” before matching
Record all of the following, not just a gene name:
- Patient and disease: pathology, primary site, histologic subtype, stage and current disease status.
- Specimen: tissue or plasma, collection site and date, primary or metastasis, fixation, tumour percentage and sample identifier.
- Assay: laboratory, test name and version, genes and variant classes covered, detection limit, quality result and regulatory or accreditation status.
- Exact finding: standard gene and variant nomenclature, mutation or fusion partner, copy-number method, protein-expression score, MSI or TMB definition, and allele fraction where relevant.
- Interpretation: diagnostic, prognostic or predictive role; evidence tier; drug, cancer type and line of therapy to which the evidence applies.
Somatic variant standards jointly developed by AMP, ASCO and CAP recommend a tiered clinical-significance system and clear reporting of method and limitations, with ongoing reassessment as evidence changes [2]. A report’s “Tier I” may refer to that laboratory framework, not the Phase I of a trial.
Four words that must stay separate
- Pathogenic: the alteration contributes to disease biology; this does not prove that a drug will benefit this patient.
- Actionable: evidence links the alteration to a clinical action, but the action may be an approved treatment, off-label discussion, another test or a clinical trial.
- Companion diagnostic: an assay provides information essential for safe and effective use of a corresponding product [3]. The label specifies the biomarker, sample, method and therapy context.
- Trial eligible: the full current protocol is satisfied and the relevant site and cohort can enroll the patient.
A variant of uncertain significance should not be promoted into a treatment target merely because software lists a laboratory study or a drug that affects the same pathway.
Match at the alteration level, not the gene level
Different changes in one gene can have opposite meaning. A known activating mutation, loss-of-function mutation, amplification, deletion and fusion are not interchangeable. A trial may accept only specified exons, codons, fusion partners, expression thresholds or copy-number cutoffs.
Ask whether the reported alteration is explicitly listed, whether the assay detects the required variant class, and whether central confirmation is mandatory. If a report says only “positive,” obtain the full laboratory output and specimen details.
Tissue, plasma and the timing problem
Tissue preserves morphology and can support DNA, RNA, protein and microenvironment testing, but old blocks may be depleted or degraded. A single biopsy samples one place at one time; tumours can be heterogeneous and change after treatment.
Plasma circulating tumour DNA can be useful when biopsy is unsafe or for detecting resistance, but sensitivity depends on tumour shedding, burden, site and assay design. NCI notes that liquid biopsy may be used when tissue cannot be obtained, while insufficient tumour material and tumour evolution remain important limits [1]. A negative plasma result can be inconclusive rather than proof that an alteration is absent; tissue testing may be needed when clinically feasible [4].
The protocol decides whether archival tissue, fresh biopsy, plasma or a specified test is acceptable. “NGS already done” does not settle that question.
Evidence has a ladder
Evidence is strongest when a validated assay identifies the same alteration in the same disease and setting for a therapy supported by prospective clinical evidence or a regulatory indication. It becomes less direct when extrapolating across tumour types, variant classes, combination partners or preclinical models.
The ESMO ESCAT framework ranks molecular targets from ready for routine implementation through investigational or preclinical evidence to lack of actionability [5]. The particular system matters less than stating the evidence explicitly. A commercial report that puts all “potential therapies” in one list hides crucial differences.
Tissue-agnostic development deliberately studies a molecular alteration across multiple tumour types, but it still needs evidence that the biomarker, assay and drug effect can be interpreted across those cancers [6]. A tissue-agnostic hypothesis is not permission to treat every tumour carrying any change in the pathway.
How trial structures affect matching
- Basket trial: one alteration or pathway is studied across several tumour types, often in separate cohorts.
- Umbrella trial: one tumour type is divided into biomarker-defined treatment arms.
- Platform or master protocol: arms may open, close or change while the overall protocol continues.
- Enrichment trial: only biomarker-positive patients enter.
- All-comers with stratification: biomarker status may define analysis rather than eligibility.
NCI-MATCH screened nearly 6,000 patients and assigned 1,593 to 38 molecular substudies; among the initial 27 reported substudies, seven met the study’s signal-seeking definition of positive [7]. The lesson is not that matching fails, but that finding an alteration, obtaining an assignment and observing meaningful activity are three separate probabilities.
From report to a Chinese trial site
For each candidate, create a one-line match record:
trial ID → Chinese site → exact arm/cohort → required alteration → accepted assay/sample → disease/line → recruitment confirmation date
Then ask the site:
- Is this arm open here, with an available slot?
- Will an overseas laboratory report be accepted for pre-screening?
- Is central retesting required, and who pays for it?
- Are the block, slides or extracted nucleic acid acceptable, and can they be shipped lawfully?
- What minimum tissue, tumour percentage and recency apply?
- Does a negative result permit another specimen or method?
- What non-biomarker criteria are common reasons for screen failure?
China regulates in-vitro diagnostic reagents and their clinical evidence, and NMPA has issued specific technical-review guidance for oncology companion diagnostics [8]. Regulatory status in another country does not automatically establish acceptance by a Chinese trial laboratory. The protocol and site laboratory manual govern trial screening.
Do not forget the rest of eligibility
Even a confirmed alteration does not override pathology, disease stage, measurable lesions, prior therapies, resistance definitions, washout, unresolved toxicity, performance status, organ function, infection, brain metastases, concomitant medicines or reproductive-safety rules. A site may need original images, treatment dates and laboratory units to apply these criteria.
Timing also matters. While central testing is pending, the disease may worsen or a standard treatment may begin and change eligibility. Ask both the trial investigator and treating oncologist how long it is medically safe to wait. Never delay urgent care for a theoretical molecular match.
Molecular tumour-board review
A useful molecular review connects laboratory findings to the pathology and treatment timeline. Its written output should separate:
- standard-care options available now;
- trial options with exact IDs and cohorts;
- evidence from another tumour type or drug class;
- resistance alterations and contraindicating findings;
- variants with no current clinical action;
- germline findings that require confirmatory testing and genetic counselling.
It should also document why the preferred specimen and test were chosen, what could have been missed, and when retesting might be justified. “No actionable mutation” means no supported action was identified under the tested scope and current evidence—not that the cancer has no molecular changes.
A safe matching endpoint
The final pre-screen package should contain the pathology report, complete molecular report, sample provenance, treatment timeline, recent imaging, performance status, current medicines and key laboratory results. The site, not a matching vendor, must confirm eligibility.
Keep standard treatment and symptom control visible alongside research. Precision oncology is most useful when it narrows uncertainty honestly; it becomes dangerous when the molecular language is used to overstate certainty.
Medical disclaimer: This guide is educational and does not interpret an individual genomic report or recommend a trial. Molecular findings require review by the relevant laboratory, oncology team and study investigator.
FAQ
Does an “actionable” mutation guarantee a matching trial?
No. Actionability can include approved care, off-label evidence or an investigational hypothesis. The exact variant, cancer context, assay, protocol criteria, site and open cohort must all match.
Should I repeat an old tumour test?
Sometimes. Retesting may be useful after disease evolution or treatment resistance, but biopsy safety, tissue adequacy, the decision to be changed and the protocol’s accepted specimens should guide it.
Is a negative liquid biopsy enough to rule out a target?
Not always. Low tumour shedding can cause a non-informative negative result. When clinically feasible and relevant, the team may recommend tissue testing or another validated method.
Can a variant of uncertain significance qualify me for treatment?
Usually not by itself. A VUS lacks sufficient evidence for clinical action. A trial can study exploratory variants only if its protocol explicitly accepts them.
Who makes the final precision-trial match?
The study investigator applies the current protocol. A molecular tumour board or matching service can rank candidates, but cannot guarantee eligibility or a slot.
Sources
- US National Cancer Institute — Biomarker Testing for Cancer Treatment
- AMP, ASCO and CAP — Standards for Interpretation and Reporting of Sequence Variants in Cancer
- US Food and Drug Administration — Companion Diagnostics
- US National Cancer Institute — Liquid Biopsy and False-Negative Results
- European Society for Medical Oncology Working Group — ESCAT Evidence Framework
- US Food and Drug Administration — Tissue-Agnostic Drug Development in Oncology
- NCI-MATCH Investigators — Lessons for Precision Oncology
- National Medical Products Administration of China — Technical Review Guidance for Oncology Companion Diagnostic Reagents
Image Review
- Decision: Approved and retained as hero-reviewed.png.
- Editorial note: The image connects DNA, a molecular target and a selected patient cohort within a China-based oncology discussion. It supports biomarker matching without showing a specific drug, test result or guaranteed benefit.